AF
NKTR icon

Amalgamated Financial’s Nektar Therapeutics NKTR Stock Holding History

Amalgamated Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$455K Buy
+5,633
New +$834K ﹤0.01% 1557

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Amalgamated Financial's NKTR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Nektar Therapeutics (NKTR) in Q1 2022: 5,633 shares worth $455K. The stake represents ﹤0.01% of the portfolio and ranks #1557 among its holdings.

240 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • Amalgamated Financial held 5,633 shares of Nektar Therapeutics worth $455K as of Q1 2022.
  • Nektar Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Nektar Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1557 holding.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.